Cilostazol Prevents Progression of Asymptomatic Carotid Artery Stenosis in Patients with Contralateral Carotid Artery Stenting

References

1. 1.↵
   Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991;325:445–53

   CrossRefPubMedWeb of Science
2. 2.↵
   Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273:1421–28

   CrossRefPubMedWeb of Science
3. 3.
   Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–87

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Halliday A,
   2. Mansfield A,
   3. Marro J,
   4. et al

   . Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004;363:1491–502

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Yadav JS,
   2. Wholey MH,
   3. Kuntz RE,
   4. et al

   . Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493–501

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Mas JL,
   2. Chatellier G,
   3. Beyssen B,
   4. et al

   . Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660–71

   CrossRefPubMedWeb of Science
7. 7.
   1. Ringleb PA,
   2. Allenberg J,
   3. Bruckmann H,
   4. et al

   . 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006;368:1239–47

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Ederle J,
   2. Dobson J,
   3. Featherstone RL,
   4. et al

   . Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010;375:985–97

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Brott TG,
   2. Hobson RW 2nd.,
   3. Howard G,
   4. et al

   . Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11–23

   CrossRefPubMedWeb of Science
10. 10.↵
    1. AbuRahma AF,
    2. Cook CC,
    3. Metz MJ,
    4. et al

    . Natural history of carotid artery stenosis contralateral to endarterectomy: results from two randomized prospective trials. J Vasc Surg 2003;38:1154–61

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Raman KG,
    2. Layne S,
    3. Makaroun MS,
    4. et al

    . Disease progression in contralateral carotid artery is common after endarterectomy. J Vasc Surg 2004;39:52–57

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Ballotta E,
    2. Da Giau G,
    3. Meneghetti G,
    4. et al

    . Progression of atherosclerosis in asymptomatic carotid arteries after contralateral endarterectomy: a 10-year prospective study. J Vasc Surg 2007;45:516–22

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Fluri F,
    2. Engelter ST,
    3. Wasner M,
    4. et al

    . The probability of restenosis, contralateral disease progression, and late neurologic events following carotid endarterectomy: a long-term follow-up study. Cerebrovasc Dis 2008;26:654–58

    CrossRefPubMed
14. 14.↵
    1. Chaturvedi S,
    2. Yadav JS

    . The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke 2006;37:1572–77

    Abstract/FREE Full Text
15. 15.↵
    1. Iida O,
    2. Nanto S,
    3. Uematsu M,
    4. et al

    . Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008;48:144–49

    CrossRefPubMed
16. 16.
    1. Ishii H,
    2. Kumada Y,
    3. Toriyama T,
    4. et al

    . Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol 2008;3:1034–40

    Abstract/FREE Full Text
17. 17.
    1. Soga Y,
    2. Yokoi H,
    3. Kawasaki T,
    4. et al

    . Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009;53:48–53

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Soga Y,
    2. Iida O,
    3. Hirano K,
    4. et al

    . Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 2010;52:608–15

    CrossRefPubMed
19. 19.
    1. Suzuki K,
    2. Iida O,
    3. Soga Y,
    4. et al

    . Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry. Circ J 2011;75:939–44

    CrossRefPubMed
20. 20.↵
    1. Douglas JS Jr.,
    2. Holmes DR Jr.,
    3. Kereiakes DJ,
    4. et al

    . Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826–32

    Abstract/FREE Full Text
21. 21.
    1. Ahn Y,
    2. Jeong MH,
    3. Jeong JW,
    4. et al

    . Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients–clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008;72:35–39

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Biondi-Zoccai GG,
    2. Lotrionte M,
    3. Anselmino M,
    4. et al

    . Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008;155:1081–89

    CrossRefPubMedWeb of Science
23. 23.
    1. Lee SW,
    2. Park SW,
    3. Kim YH,
    4. et al

    . Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181–87

    CrossRefPubMedWeb of Science
24. 24.
    1. Jennings DL,
    2. Kalus JS

    . Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol 2010;50:415–21

    CrossRefPubMed
25. 25.
    1. Dihu JB,
    2. Abudayyeh I,
    3. Saudye HA,
    4. et al

    . Cilostazol: a potential therapeutic option to prevent in-stent restenosis. J Am Coll Cardiol 2011;57:2035–36

    CrossRefPubMed
26. 26.↵
    1. Lee SW,
    2. Park SW,
    3. Kim YH,
    4. et al

    . A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011;57:1264–70

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Takigawa T,
    2. Matsumaru Y,
    3. Hayakawa M,
    4. et al

    . Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010;51:51–56

    CrossRefPubMed
28. 28.↵
    1. Yamagami H,
    2. Sakai N,
    3. Matsumaru Y,
    4. et al

    . Periprocedural cilostazol treatment and restenosis after carotid artery stenting: The Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS). J Stroke Cerebrovasc Dis 2012;21:193–99

    CrossRefPubMed
29. 29.↵
    1. Yoshimoto T,
    2. Fujimoto S,
    3. Muraki M,
    4. et al

    . Cilostazol may suppress restenosis and new contralateral carotid artery stenosis after carotid endarterectomy. Neurol Med Chir (Tokyo) 2010;50:525–29

    CrossRefPubMed
30. 30.↵
    1. Kato T,
    2. Sakai H,
    3. Tsujimoto M,
    4. et al

    . Prolonged carotid sinus reflex is a risk factor for contrast-induced nephropathy following carotid artery stenting. AJNR Am J Neuroradiol 2011;32:441–45

    Abstract/FREE Full Text
31. 31.↵
    1. Jahromi AS,
    2. Cina CS,
    3. Liu Y,
    4. et al

    . Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. J Vasc Surg 2005;41:962–72

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Rockman CB,
    2. Riles TS,
    3. Lamparello PJ,
    4. et al

    . Natural history and management of the asymptomatic, moderately stenotic internal carotid artery. J Vasc Surg 1997;25:423–31

    CrossRefPubMedWeb of Science
33. 33.
    1. Olin JW,
    2. Fonseca C,
    3. Childs MB,
    4. et al

    . The natural history of asymptomatic moderate internal carotid artery stenosis by duplex ultrasound. Vasc Med 1998;3:101–08

    Abstract/FREE Full Text
34. 34.↵
    1. Mansour MA,
    2. Littooy FN,
    3. Watson WC,
    4. et al

    . Outcome of moderate carotid artery stenosis in patients who are asymptomatic. J Vasc Surg 1999;29:217–25

    CrossRefPubMedWeb of Science
35. 35.
    1. Muluk SC,
    2. Muluk VS,
    3. Sugimoto H,
    4. et al

    . Progression of asymptomatic carotid stenosis: a natural history study in 1004 patients. J Vasc Surg 1999;29:208–14

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Liapis C,
    2. Kakisis J,
    3. Papavassiliou V,
    4. et al

    . Internal carotid artery stenosis: rate of progression. Eur J Vasc Endovasc Surg 2000;19:111–17

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Cinà CS,
    2. Safar HA,
    3. Maggisano R,
    4. et al

    . Prevalence and progression of internal carotid artery stenosis in patients with peripheral arterial occlusive disease. J Vasc Surg 2002;36:75–82

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Jahromi AS,
    2. Clase CM,
    3. Maggisano R,
    4. et al

    . Progression of internal carotid artery stenosis in patients with peripheral arterial occlusive disease. J Vasc Surg 2009;50:292–98

    CrossRefPubMed
39. 39.↵
    1. Libby P

    . Inflammation in atherosclerosis. Nature 2002;420:868–74

    CrossRefPubMedWeb of Science
40. 40.↵
    1. de Weerd M,
    2. Greving JP,
    3. Hedblad B,
    4. et al

    . Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010;41:1294–97

    Abstract/FREE Full Text
41. 41.↵
    1. Qureshi AI,
    2. Janardhan V,
    3. Bennett SE,
    4. et al

    . Who should be screened for asymptomatic carotid artery stenosis? Experience from the Western New York Stroke Screening Program. J Neuroimaging 2001;11:105–11

    PubMedWeb of Science
42. 42.
    1. Marek J,
    2. Mills JL,
    3. Harvich J,
    4. et al

    . Utility of routine carotid duplex screening in patients who have claudication. J Vasc Surg 1996;24:572–77; discussion 577–79

    CrossRefPubMedWeb of Science
43. 43.
    1. Fine-Edelstein JS,
    2. Wolf PA,
    3. O'Leary DH,
    4. et al

    . Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994;44:1046–50

    Abstract/FREE Full Text
44. 44.↵
    1. O'Leary DH,
    2. Polak JF,
    3. Kronmal RA,
    4. et al

    . Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992;23:1752–60

    Abstract/FREE Full Text
45. 45.↵
    1. Bhatt DL,
    2. Eagle KA,
    3. Ohman EM,
    4. et al

    . Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350–57

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Bhatt DL,
    2. Steg PG,
    3. Ohman EM,
    4. et al

    . International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180–89

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Nicolaides AN,
    2. Kakkos SK,
    3. Griffin M,
    4. et al

    . Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Eur J Vasc Endovasc Surg 2005;30:275–84

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Abbott AL

    . Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009;40:e573–83

    Abstract/FREE Full Text
49. 49.↵
    1. Han Y,
    2. Wang S,
    3. Li Y,
    4. et al

    . Cilostazol improves long-term outcomes after coronary stent implantation. Am Heart J 2005;150: 568
50. 50.↵
    1. Lee SW,
    2. Chun KJ,
    3. Park SW,
    4. et al

    . Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 2010;105:168–73

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Kwon SU,
    2. Cho YJ,
    3. Koo JS,
    4. et al

    . Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782–86

    Abstract/FREE Full Text
52. 52.↵
    1. Shinohara Y,
    2. Katayama Y,
    3. Uchiyama S,
    4. et al

    . Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–68

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Ikeda Y,
    2. Kikuchi M,
    3. Murakami H,
    4. et al

    . Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Drug Research 1987;37:563–66

    PubMed
54. 54.
    1. Tanaka T,
    2. Ishikawa T,
    3. Hagiwara M,
    4. et al

    . Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988;36:313–20

    PubMedWeb of Science
55. 55.
    1. Tanaka K,
    2. Gotoh F,
    3. Fukuuchi Y,
    4. et al

    . Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989;20:668–73

    Abstract/FREE Full Text
56. 56.↵
    1. Ishiguro M,
    2. Mishiro K,
    3. Fujiwara Y,
    4. et al

    . Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010;5: e15178